咖啡因通过阻断腺A1受体阻断炎症性疼痛的针止痛功能受损
Xiang Cui1, Wan Wei2, Ziyi Zhang1
1Department of Physiology, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
The journal of pain
|November 2, 2023
概括
咖啡因通过抑制腺A1受体来阻断针疼痛的缓解. 建议在针治疗期间避免摄入咖啡因,以确保治疗的有效性,特别是在疼痛管理方面.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 疼痛研究 疼痛研究
背景情况:
- 咖啡因与针止痛的相互作用受到争议,其中涉及到腺信号传递.
- 氨酸A1受体 (A1R) 是咖啡因对缓解疼痛作用的潜在调解者.
研究的目的:
- 为了研究腺A1受体 (A1R) 在咖啡因抑制针止痛的作用.
- 评估咖啡因对野生类型和A1R淘汰小鼠疼痛感知和针疗法的影响.
主要方法:
- 使用了A1R淘汰赛小鼠和野生类型的 littermates.
- 测量疼痛值 (机械,热) 和炎症性疼痛模型 (形式素,CFA).
- 采用C纤维反射电肌学来验证发现.
主要成果:
- 对于正常的感官感知或炎症性疼痛过敏,A1R并不是必不可少的.
- 针的止痛作用在A1R淘汰小鼠中减少.
- 咖啡因抑制了野生类型小鼠的电 (EA) 止痛作用,但不是A1R淘汰小鼠.
- 咖啡因通过阻断A1R减少了EA镇痛作用.
结论:
- 氨酸A1受体调解咖啡因对针止痛的抑制作用.
- 咖啡因消耗可能会干扰针治疗缓解疼痛的有效性.
- 监测咖啡因摄入量对于优化针治疗至关重要.
相关概念视频
Analgesia and Pain Management
634
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
634
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
869
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
869
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
891
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
891


